MicroRNAs: Role in hepatitis C virus pathogenesis

Shubham Shrivastava a, Robert Steele a, Ranjit Ray b, Ratna B. Ray a,*

a Department of Pathology, Saint Louis University, St. Louis, MO, USA
b Department of Internal Medicine, Saint Louis University, St. Louis, MO, USA

Received 3 December 2014; accepted 1 January 2015
Available online 12 January 2015

Abstract  Hepatitis C virus (HCV) is a global health burden with an estimated 170–200 million peoples chronically infected worldwide. HCV infection remains as an independent risk factor for chronic hepatitis, liver cirrhosis, hepatocellular carcinoma, and a major reason for liver transplantation. Discovery of direct acting antiviral (DAA) drugs have shown promising results with more than 90% success rate in clearing the HCV RNA in patients, although long-term consequences remain to be evaluated. microRNAs (miRNAs) are important players in establishment of HCV infection and target crucial host cellular factors needed for productive HCV replication and augmented cell growth. Altered expression of miRNAs is involved in the pathogenesis associated with HCV infection by controlling signaling pathways such as immune response, proliferation and apoptosis. miRNA is emerging as a means of communication between various cell types inside the liver. There is likely possibility of developing circulating miRNAs as biomarkers of disease progression and can also serve as diagnostic tool with potential of early therapeutic intervention in HCV associated end stage liver disease. This review focuses on recent studies highlighting the contribution of miRNAs in HCV life cycle and their coordinated regulation in HCV mediated liver disease progression.

* Corresponding author. Department of Pathology, Saint Louis University, DRC 207, 1100 South Grand Boulevard, St. Louis, MO 63104, USA.
Tel.: +1 314 977 7822; fax: +1 314 771 3816.
E-mail address: rayrb@slu.edu (R.B. Ray).

Peer review under responsibility of Chongqing Medical University.

http://dx.doi.org/10.1016/j.gendis.2015.01.001
2352-3042/© 2015, Chongqing Medical University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Hepatitis C virus (HCV) is a hepatotropic, enveloped, single stranded and positive sense RNA virus belongs to family flaviviridae and genus hepacivirus. The viral genome contains 5' and 3' untranslated regions (UTR) that are important for viral replication and translation. An internal ribosome entry site (IRES) directs the synthesis of a single precursor polyprotein of approximately 3010 amino acids, which is cleaved by viral and cellular proteases into three structural (core, E1 and E2) and seven non-structural (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) viral proteins. Core protein forms the capsid, which is surrounded by a lipid bilayer containing the glycoproteins, E1 and E2. These viral proteins both singly or in coordinated manner interact with host cellular factors and regulate various signaling pathways to facilitate virus mediated persistent infection.

HCV is a major cause of chronic liver disease, mostly asymptomatic in nature. Majority of infected patients, approximately 80%, develop persistent chronic infection and are at high risk for liver cirrhosis and hepatocellular carcinoma (HCC). An estimated 170–200 million peoples worldwide are infected with hepatitis C virus and about 2.7–3.9 million peoples are living with HCV infection in the United States. In addition, HCC and cirrhosis have been increasing among persons infected with HCV. Advances in anti-HCV therapy have moved into a new era with interferon (IFN)-free regimens. Treatment options are evolving and the once difficult to treat genotype (genotype 1) has shown significant improvements in sustained virologic response (SVR) rates. All-oral, IFN-free combinations of drugs are expected to cure more than 90% of infections. Direct-acting antivirals (DAAs) target non-structural proteins of HCV resulting in the termination of viral replication. Several antiviral drugs targeting viral and host factors essential for productive HCV infection are depicted in Fig. 1. The first NS3/4A protease inhibitors boceprevir (Merck, Whitehouse Station, NJ) and telaprevir (Vertex Pharmaceuticals, Cambridge, MA) have shown improved rate of SVR in genotype 1 HCV infected patients in compared with standard pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, but their toxicities combined with PEG-IFN and RBV limited their overall efficacy.

Figure 1  Anti-HCV drugs targeting viral life cycle. (1) HCV viral particle interacts with several entry factors such as, SR-B1, CD81, CLDN1 and OCLN to enter the hepatocytes. Entry inhibitor, ITX-5061 inhibits the uptake of viral particles through SR-B1. (2) Once inside the cell, virus releases its genome by the process of uncoating. (3) The viral RNA is translated and the resulting polyprotein is processed at the endoplasmic reticulum. NS3/4A protease inhibitors inhibit viral protein synthesis and impair interferon signaling pathway. (4) Replication takes place in ER-derived membrane compartment, called as membranous web composed of single-, double-, multi-membraned vesicles and lipid droplets. miR-122 binding to viral genome enhances viral replication and translation. Drugs targeting NS5A and NS5B block viral replication. CypA interacts with NS5A and required for viral replication. Nucleocapsid is formed after interaction of core and NS5A protein with lipid droplets. The p7, NS2 and NS3-NS4A proteins are also involved in coordination of virus assembly. (5) HCV virion morphogenesis is coupled to the very-low density lipoproteins (VLDL) secretory pathway, and virus particles are released as lipoviroparticles (LVPs). Viral proteins and host factors that are the targets of direct-acting antivirals (DAAs) in advanced clinical development are indicated in the legend. CLDN1, claudin 1; CypA, cyclophilin A; miR, microRNA; OCLN, occludin; SR-B1, scavenger receptor class B member 1; LD, lipid droplets.
miRNA in HCV infection

Simeprevir (Janssen Pharmaceuticals, Titusville, NJ), faldaprevir, and asunaprevir are second-wave, first-generation NS3/4A inhibitors that have already been or will soon be approved. Second-generation protease inhibitors are in clinical trials. Daclatasvir (BMS-790052, Bristol-Myers Squibb Company) is the first approved DAA belonging to the class of NS5A replication complex inhibitors. The potency of daclatasvir is very high, and this drug is an important component of combination regimens for all genotypes. Sofosbuvir, the first approved NS5B polymerase inhibitor (Gilead Sciences, Foster City, CA) has shown high potency and lower drug resistance in clinical trials. DAA drugs as anti-HCV therapeutics is highly encouraging.7,8 However, the efficacy of these new therapeutic options for cirrhotic patients, the most-difficult-to-treat population and long-term follow-up data will be needed to confirm the excellent outcome of SVR and liver pathogenesis. An alternative or complementary approach to treat HCV infection is by targeting host factors that support viral life cycle. Identifying host factors have emerged as a promising alternative since they will have a high barrier for viral resistance and can be broadly effective against all HCV genotypes.10 Several host factors were identified by using high throughput gene silencing screening approaches that helps in HCV entry, replication, assembly and release. The most promising host factors are miR-122, cyclophilin A (Cyp A), scavenger receptor (SR)-BI and phosphatidylinositol-4-kinase III α. Drugs targeting HCV entry factors, such as SR-BI may prevent the initiation of new infection. Cyclophilins are important host factors required for viral replication and Cyp A has been shown to interact with NS5A.10,11 The liver specific miR-122 binds to the 5’ UTR of the HCV genome and helps in viral replication and enhances viral protein synthesis.12-15 Drugs targeting host factors, such as small molecule inhibitor of SR-BI (ITX 5061) and cyclophilin inhibitors, alisporivir (Debo-025, Novartis) are in clinical trials.7,10,11 Anti-HCV therapeutics targeting miR-122 showed reduction in HCV viremia with no evidence of viral resistance and minimal side effects in chimpanzees chronically infected with hepatitis C.16 In addition, Miravirsen (a locked nucleic acid-modified antisense oligonucleotide for miR-122) showed prolonged dose-dependent reductions in HCV RNA levels in chronic HCV genotype 1 infected patients in Phase IIa clinical trials by Santaris Pharma (Copenhagen, Denmark).17 These alternative approaches targeting host factors in combination with current DAA drugs will help in strengthening the host’s innate immunity as well as interfere with host factors required for HCV induced pathogenesis.

MicroRNA biogenesis and its regulation

MicroRNAs (miRNAs) were discovered in 1993 during a developmental timing experiment in the nematode Caenorhabditis elegans. Currently, human miRNA family has expanded to 2588 mature miRNAs (miRBase v21.0; http://www.mirbase.org/) and in silico prediction estimates that approximately 60% of human message RNA (mRNA) could be targets of miRNA. These miRNAs account for only 1% of the human genome. miRNAs are highly conserved in nearly all organisms and constitute a class of non-coding RNAs, about 18–22 nucleotides long and play a crucial role in the regulation of gene expression.18,19 Genes encoding miRNAs are transcribed by RNA polymerase II and form transcripts as primary miRNAs (pri-miRNAs). pri-miRNAs are processed by ribonuclease Drosha to produce precursor miRNAs (pre-miRNAs) which is exported into the cytoplasm and cleaved by the ribonuclease Dicer to produce mature, single stranded miRNAs.19,20 Once synthesized, mature miRNA binds to two proteins, GW182 and Argonaute/EIF2C (AGO) family proteins and forms a complex called miRNA induced silencing complex (miRISC) and mediate the target mRNA recognition (Fig. 2). miRNA regulation takes place at multiple steps, including their transcription, their processing by Drosha and Dicer, their loading onto AGO proteins and miRNA turnover.20,21 miRNA transcription is controlled by RNA Pol II-associated transcription factors and epigenetic regulators. Transcription factors, such as p53, MYC, ZEB1 and ZEB2, and myoblast determination protein 1 (MYOD1) positively or negatively regulate miRNA expression. Epigenetic control, such as DNA methylation and histone modifications also contribute to miRNA gene regulation. miRNA identify target mRNA through specific base-pairing in-
Many miRNA genes are located in chromosomal regions frequently involved in chromosomal alterations such as deletion or amplification during tumor development. Therefore, it is not surprising that dysregulation of miRNA networks have been associated with cancer progression.

Virus-host interactions also involve several regulatory steps to control gene expression and one of them is changes in cellular miRNA expression profiles. Cellular miRNAs control protein expression that may influence cellular tropism of viruses, modulate viral infectivity, and play a crucial role in inducing appropriate antiviral immune responses. Several RNA viruses have evolved mechanisms to degrade, boost, or hijack cellular miRNAs to benefit the viral life cycle. HCV infection exerts a profound effect on the expression of cellular miRNAs. Some of the cellular miRNAs affect viral replication directly by binding to the viral genome or indirectly by targeting host factors.

Direct interaction of cellular miRNAs to the HCV genome

Recent studies have identified several miRNAs as key players in virus-host interactions, regulating virus replication and pathogenesis during HCV infection. The role of miR-122 in HCV infection was first demonstrated by sequestration of endogenous miR-122 that led to a substantial reduction in HCV RNA abundance. miR-122 binds directly to 5' UTR of the virus genome at two adjacent sites in association with Ago2. It forms an oligomeric complex in which one miR-122 molecule binds to the 5' UTR of HCV RNA with 3' overhanging nucleotides, masking the 5' terminal sequences from nucleolytic degradation, thereby promoting viral RNA stability and propagation of HCV genome. Furthermore, specific internal nucleotides as well as 3' terminal nucleotides in miR-122 were absolutely required for maintaining HCV RNA. Recent study also demonstrated that miR-122 protects HCV RNA from 5' decay by targeting 5' exonuclease Xrn1. HCV genome harbors two more miR-122 target sites, one in the variable region of the 3' UTR and the other in the NS5B coding region. However, miR-122 binding to NS5B and 3' UTR impairs HCV RNA replication and translation. Exogenous expression of miR-122 allows efficient HCV RNA replication and/or infectious virion production in non-permissive cell line. Besides miR-122, other miRNAs such as, miR-448, miR-196, miR-199a, let-7b and miR-181c have been reported to interact directly with HCV genome, however, upon binding to HCV RNA, they
inhibit HCV replication (Fig. 3). Overexpression of miR-448 and miR-196 were able to substantially attenuate viral replication by directly targeting Core and NS5A coding region of the HCV genome, respectively. Overexpression of miR-199a inhibited HCV replication in cells bearing HCV-1b or -2a genome length replicon on binding to stem-loop II region of 5'UTR of HCV genome. Let-7b was also reported to directly target HCV genome and elicits anti-HCV activity. Mutational analysis identified let-7b binding sites at the coding sequences of NS5B and 5'UTR of HCV genome that were conserved among various HCV genotypes. We have recently showed that miR-181c is a novel miRNA that binds to E1 and NS5A regions of HCV genome and overexpression of miR-181c reduces the viral replication. However, miR-181c binding efficiency to genotype 1a and genotype 2a specific HCV genome is different. Thus, further work is needed to understand the association between different genotypes of HCV genome and miRNAs.

**Cellular miRNAs that regulates HCV replication by targeting interferon signaling pathway**

HCV has developed several strategies to evade the IFN signaling pathway to facilitate its own replication. HCV evades type I IFN pathway by inducing miRNAs that regulate the expression of target genes involved in innate immune response to viral infections. The direct correlation of cellular miRNA in regulating type I IFN signaling pathway to promote HCV replication was demonstrated by our group. We established that HCV induces the expression of miR-130a to evade IFN response by targeting IFITM1. Our study demonstrated that miR-130a expression was upregulated in liver biopsy from HCV infected patients as well as in HCV infected hepatocytes in vitro. Knockdown of miR-130a enhances IFITM1 expression that possesses anti-HCV activity. During IFN treatment, IFITM1 accumulates at hepatic tight junctions in the liver of HCV-infected patients and then, interacts with HCV co-receptors, including CD81 and occludin, to disrupt the process of viral entry. Similar observation of reduced HCV RNA copies was reported in anti-miR-130a transfected virus infected cells. Subsequently, miR-130a expression was correlated with genes involved in transforming growth factor beta (TGF-β) signaling pathway and found to be reduced in HCV infection and upregulated on IFN treatment. However, another study reported that overexpression of miR-130a inhibited HCV replication by restoring the expression of endogenous IFN-α and IFN-β and interferon stimulated genes, MxA, ISG15 and USP18 respectively, in TLR3 and RIG-I deficient hepatocytes. Upregulated miR-21 suppressed MyD88 and IRAK1 expression in HCV infected hepatocytes, which subsequently repressed type I IFN effector gene expression and the type I IFN-mediated antiviral response, thereby promoting viral replication. In a separate study, upregulation of miR-758 expression was reported in HCV infected patients and shown to be negatively correlated with decrease in TLR3 and TLR7 expression levels and thereby, reduced IFN-α and IFN-β production to impair innate immune response. Overexpression of miR-122 has also been associated with inhibition of IFN signaling pathway. Silencing of miR-122 enhances IFN-induced ISRE activity by decreasing expression of SOCS3. This decrease in SOCS3 level was also regulated by enhanced methylation at SOCS3 gene promoter, implicating additional mechanism of inhibition of HCV replication using antisense oligonucleotides of miR-122. Recently, SOCS1 and SOCS3 were identified as the targets of miR-221 and overexpression of miR-221 was shown to accelerate anti-HCV effect of IFN-α in HCV infected hepatocytes. IFN-α treatment also modulates HCV-specific miRNAs expression in hepatocytes. miR-324-5p and miR-489 were shown to be upregulated in the presence of IFN-α while differential expression of miR-30c and miR-130a were observed between HCV-infected Huh7.5 cells treated with or without IFN-α. miR-30 cluster targets SOCS1 and SOCS3 genes that act as negative regulators of cytokine signaling. Specifically, SOCS1 and SOCS3 inhibit JAK tyrosine kinase activity and STATs in the JAK-STAT signaling pathway suggesting that IFN-α induced miRNAs modulates gene expression in HCV infected hepatocytes. IFN-β treatment of Huh7 cells showed an upregulation of miR-142-3p and miR-128a, and these miRNAs were downregulated in HCV replicon-expressing cells. IFN-β induced miRNAs, in conjunction with downregulation of miR-122, were also studied to prevent HCV replication. Introduction of anti-miRs against miR-196, miR-296, miR-351, miR-431 and miR-448, with and without the inclusion of miR-122 mimic, attenuated the IFN-β mediated reduction of viral RNA by ~75%. In a recent study, a set of 750 miRNAs expression profiles was generated in response to IFN-α and

**Figure 3** Cellular miRNAs targeting HCV genome. The binding of two copies of miR-122 within the 5' UTR of the HCV genome enhances viral replication and translation. The binding of miR-199a at 5'UTR inhibits viral replication. Let-7b interacts with viral genome at two different locations, 5'UTR and NS5B coding region. miR-448 targets Core and miR-196 targets NS5A of the HCV genome. miR-181c inhibits viral replication by targeting E1 and NS5A regions of viral genome.
interleukin (IL)-28B treatment to hepatocytes. Let-7b was shown to inhibit HCV replication and viral protein translation by targeting host factor insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1). Furthermore, inhibition of let-7b attenuated the anti-HCV effects of IFN-α and IL-28B.52 We recently observed that miR-373 was upregulated during HCV infection and negatively regulated type I IFN signaling pathway by suppressing JAK1 and IRF9 (unpublished observation). Together, these observations suggest that type I and type III IFNs induced host miRNAs directly involved in regulation of HCV replication and infectivity along with targeting host factors resulting in additional mode of virus restriction.

**Cellular miRNAs in response to IFN therapy and HCV infection**

Increasing evidence suggests that miRNAs have a profound impact on host defense to HCV infection and clinical outcome of standard HCV therapy. miRNA expression profiles were examined to identify the miRNAs associated with the standard treatment (IFN-α with RBV) to chronic hepatitis C (CHC) patients. Expression levels of 9 miRNAs (upregulated: miR-27b, miR-122, miR-378 and miR-422b; downregulated: miR-18a, miR-34b, miR-143, miR-145 and miR-652) were significantly different in the SVR and non-responder (NR) groups, suggesting that expression pattern of these hepatic miRNA are associated with the therapeutic outcome in CHC patients.53 The expression level of hepatic miR-122 was reportedly associated with early response to IFN treatment. HCV infected patients who did not respond to therapy had significantly lower miR-122 levels as compared to responder.54 In addition, an association between miR-122, IFN-λ3 polymorphism and outcome to IFN therapy was examined in chronic HCV patients. HCV infected patients with IFN-λ3 CC genotype, favorable outcome to therapy, were associated with increased heptic expression of miR-122. Interestingly, during PEG-IFN/RBV therapy, patients with the IFN-λ3 CC genotype had a more rapid early HCV viral decline than patients with CT/T genotype and a stronger association of miR-122 was established observation. Together, these observations suggest that type I and type III IFNs induced host miRNAs directly involved in regulation of HCV replication and infectivity along with targeting host factors resulting in additional mode of virus restriction.

HCV modulates the expression of miRNAs to regulate critical gene networks that help in determining viral load, clearance and HCV related disease progression. Recently, in vivo kinetics of hepatic and serum miR-122 and viral replication was studied in HCV infected chimpanzees to understand the complexities of the virus-host interaction during the acute phase of HCV infection. It was observed that during acute infection (first 4 weeks) there was rise in hepatic miR-122 levels indicating the significance of miR-122 in viral replication. However, in later time points (10–14 weeks), an inverse correlation between hepatic miR-122 and HCV RNA in the liver and serum was noted. Subsequently, there is rise of hepatic miR-122 level during HCV clearance and alanine leucine transaminase (ALT) normalization suggesting a tri-phasic relationship among hepatic miR-122 expression and viral RNA levels during HCV infection.66 Apart from regulating viral replication, miR-122 is also involved in cell cycle progression in hepatoma cell line by regulating viral translation.64 Ectopic expression of miR-122 promotes HCV IRES dependent translation during the G0 and G1 phase of cell cycle.64 Alcohol consumption increases viral replication by regulating miR-122 and cyclin G1 expression and use of miR-122 inhibitor has been reported to prevent alcohol-induced increase in HCV RNA and protein levels.65 In addition, alcohol consumption enhances miR-122 expression by increasing the expression levels of GW182 and heat shock protein 90 further promoting HCV replication.66 Overexpression of miR-122 also decreases HCV entry into hepatocytes through down-regulation of occludin.67 Apart from directly targeting the viral genome, miR-196a targets Bach1, a repressor of anti-oxidative and anti-inflammatory gene networks (HMOX1) expression.68 HCV RNA and NS5A protein expression in subgenomic replicon.68 In addition, higher HMOX1 expression was correlated with higher expression of Bach1 and miR-122 in
chronic HCV patients. Several miRNA profiling studies have demonstrated alterations in miRNAs expression and identified miRNA-mRNA regulatory networks during HCV infection. Differential upregulation of hsa-miR-130a, hsa-miR-130b, hsa-miR-298, hsa-miR-193a-5p and hsa-miR-371-5p were observed in HCV Con1 replicon in comparison to control cells. These miRNAs have been associated with cell growth by targeting genes PPARG, IFR1 and STAT3 in HCV infected cells. Differential expression of miRNAs such as, miR-24, miR-149, miR-638 and miR-1181 were also identified following HCV infection and are involved in HCV entry, replication and propagation.

Chronic HCV infection is closely associated with hepatic inflammation, fibrosis, steatosis, liver cirrhosis and HCC. Chronic HCV infection induced liver fibrosis is mediated by upregulation of TGF-β. TGF-β signaling activates hepatic stellate cells (HSCs) to induce extracellular matrix production. In HCV-infected patients and in a mouse carbon tetrachloride fibrosis model, expression levels of miR-21 were higher and found to be positively correlated with fibrotic stage. miR-21 was shown to target SMAD7, a negative regulator of TGF-β signaling, leading to increased fibrogenesis. In HCV infected patients, lower expression levels of miR-29 was observed in liver and overexpression of miR-29 inhibits viral RNA in HCV infected hepatocytes. Inhibition of miR-29 was also linked with activation of HSCs and collagen synthesis. Recently, upregulation of miR-200c was linked with hepatic fibrosis in HCV patients. miR-200c reduces the expression of Fas associated phosphatase 1 (FAP1) and subsequent activation of Src kinase signaling increases the expression of collagen and fibroblast growth factor involved in fibrosis. Reduced expression of miR-449a and miR-107 was observed in chronic HCV patients but not in alcoholic and non-alcoholic liver diseases by genome wide miRNA analyses. miR-449a regulates the expression of YKL40 by targeting NOTCH signaling pathway following HCV infection. Elevated levels of YKL40 were observed in chronic HCV patients and YKL40 is known to promote the synthesis of extracellular matrix and fibrosis. Downregulation of miR-107 and miR-449a modulates the expression of CCL2 chemokine by targeting components of the interleukin-6 receptor (IL-6R) complex in patients with HCV related liver disease. miR-449a and miR-107 target IL-6R and JAK1 respectively and inhibit IL-6 signaling and impair STAT3 activation in human hepatocytes. Collectively, these reports suggest the role of miRNAs in targeting genes involved in linking inflammation and fibrosis in chronic HCV infection. The incidence of hepatic steatosis is higher in patients infected with genotype 3a of HCV. The role of miR-27 was implicated in HCV associated steatosis by two separate groups. In the first study, miR-27a was reported to targets lipid metabolism related transcription factor, RXRs and lipid transporter, ABCA1 resulting in lipid accumulation and HDL synthesis in virus infected hepatocytes. In a second study, miR-27b also induced lipid droplet accumulation in HCV infected hepatocytes by targeting peroxisome proliferator-activated receptor (PPAR-γ) and angiopoietin-like protein 3 (ANGPTL3). miR-27a expression was induced by HCV infection and HCV replication was hampered by miR-27a reflecting a negative feedback role in HCV infection. In a separate study, upregulation of miR-136 and downregulation of miR-126 and miR-181a was observed in liver biopsies of HCV infected patients with different genotypes compared with noninfected individuals. Interestingly, miR-122 and miR-126 expression levels were correlated with viral load in sera and miR-136 and miR-122 correlated with the presence of steatosis.

CHC is a major risk factor associated with HCC. miRNA dysregulation has been linked with initiation and progression of HCC, however, the role of miRNAs in HCV-related HCC is poorly understood. The identification of HCC related miRNA signatures is of great value for the early diagnosis of HCC, prior to the onset of disease in HCV-positive patients. HCV modulates miRNA expression to facilitate hepatocyte growth towards tumorigenesis by regulating various signaling pathways. We have observed reduced expression of miR-181c at the transcriptional level in HCV infected hepatocytes. miR-181c targets HOXA1 to promote hepatocyte growth by modulating Stat3 and Stat5 expression during HCV infection.

miR-192/miR-215 and miR-491 are capable of dysregulation has been linked with initiation and progression of HCC, prior to the onset of disease in HCV-positive patients. HCV modulates miRNA expression to facilitate hepatocyte growth towards tumorigenesis by regulating various signaling pathways. We have observed reduced expression of miR-181c at the transcriptional level in HCV infected hepatocytes. miR-181c targets HOXA1 to promote hepatocyte growth by modulating Stat3 and Stat5 expression during HCV infection.

miR-192/miR-215 and miR-491 are capable of dysregulation has been linked with initiation and progression of HCC, prior to the onset of disease in HCV-positive patients. HCV modulates miRNA expression to facilitate hepatocyte growth towards tumorigenesis by regulating various signaling pathways. We have observed reduced expression of miR-181c at the transcriptional level in HCV infected hepatocytes. miR-181c targets HOXA1 to promote hepatocyte growth by modulating Stat3 and Stat5 expression during HCV infection.

miR-192/miR-215 and miR-491 are capable of dysregulation has been linked with initiation and progression of HCC, prior to the onset of disease in HCV-positive patients. HCV modulates miRNA expression to facilitate hepatocyte growth towards tumorigenesis by regulating various signaling pathways. We have observed reduced expression of miR-181c at the transcriptional level in HCV infected hepatocytes. miR-181c targets HOXA1 to promote hepatocyte growth by modulating Stat3 and Stat5 expression during HCV infection.

miR-192/miR-215 and miR-491 are capable of dysregulation has been linked with initiation and progression of HCC, prior to the onset of disease in HCV-positive patients. HCV modulates miRNA expression to facilitate hepatocyte growth towards tumorigenesis by regulating various signaling pathways. We have observed reduced expression of miR-181c at the transcriptional level in HCV infected hepatocytes. miR-181c targets HOXA1 to promote hepatocyte growth by modulating Stat3 and Stat5 expression during HCV infection.

miR-192/miR-215 and miR-491 are capable of dysregulation has been linked with initiation and progression of HCC, prior to the onset of disease in HCV-positive patients. HCV modulates miRNA expression to facilitate hepatocyte growth towards tumorigenesis by regulating various signaling pathways. We have observed reduced expression of miR-181c at the transcriptional level in HCV infected hepatocytes. miR-181c targets HOXA1 to promote hepatocyte growth by modulating Stat3 and Stat5 expression during HCV infection.
intervention and improved outcome of antiviral treatment. Non-invasive or minimally invasive methods need to be developed to evaluate disease severity and the likelihood of disease progression. Circulating miRNAs might have potential value as biomarkers for detection and as predictive markers for liver disease progression in HCV infection. Circulating miRNAs are released in extracellular space and carried in various forms, including in association with Ago2, exosomes or HDL in circulation. The biological function of these circulating miRNA is still unknown in HCV infection. However, circulating miRNA might provide a means of communication to neighboring recipient cells and influence gene expression on target cells. To determine the potential of developing circulating miRNA as a predictive biomarker in HCV-related liver disease, we performed serum/plasma specific miRNA array and observed that several circulating miRNAs were significantly upregulated in sera of HCV-infected patients as compared to healthy controls. We observed increased expression of miR-20a and miR-92a in sera specific to HCV-associated liver disease but not in sera of patients with non-HCV-related liver disease. Subsequently, we observed that elevated levels of miR-20a were positively correlated with disease severity in HCV-infected patients, however, miR-92a expression was reduced with higher grade of fibrosis in HCV-infected patients. Longitudinal sample analyses suggested that miR-20a expression remained higher when disease progresses from acute to chronic infection whereas, miR-92a expression declines in response to spontaneously resolved infection. miRNA profiling was also performed to identify the expression of 940 human miRNAs in the serum of HCV-infected individuals. Serum levels of miR-134, miR-320c and miR-483-5p were significantly upregulated in HCV-infected patients. Serum levels of miR-122 were correlated with disease parameters in patients with CHC by several groups. The higher levels of miR-122 and miR-192 were observed in sera from patients with CHC and in other etiologies associated with liver injury as compared to sera from healthy controls. The serum level of miR-122 and miR-21 strongly correlates with serum ALT levels and higher necroinflammatory activity in the liver of CHC patients suggesting their potential as better serum biomarker over ALT in predicting the presence of chronic HCV infection, although the specificity of miR-122 for HCV-mediated liver disease is controversial. Reduced levels of miR-122 were observed in both serum and liver samples from patients with CHC with advanced fibrosis. During fibrosis progression, the number of hepatocytes decreases and numbers of lymphocytes, Kupffer cells, and HSCs increases. This may explain the reduced amount of miR-122 with hepatocyte loss at advanced stage of fibrosis. miR-221 was found to be upregulated in the serum of CHC patients. miR-181a expression was significantly upregulated in the serum of HCV-infected patients compared to healthy controls. The serum level of miR-122 and miR-21 strongly correlates with serum ALT levels and higher necroinflammatory activity in the liver of CHC patients, as well as liver enzymes (ALT, AST). Levels of miR-125b and miR-146a were also increased in the serum of CHC patients compared to healthy controls.

Circulating miRNAs in urine were also examined for developing screening methods. Expression of three upregulated miRNAs, miR-625, miR-532 and miR-618, were evaluated as non-invasive biomarkers for early diagnosis of HCC among high-risk HCV-positive patients. Elevated expression of miR-625, miR-532 and miR-618 were observed in 56%, 62.5% and 72% of HCC-post HCV-positive patients, respectively. In addition, miR-516-5p and miR-650 were found to be down-regulated in 50% and 72% of HCC-post HCV-positive patients, respectively. Differential expressions of these miRNAs were predicted to possibly target genes related to HCC development and progression in high-risk HCV patients. Further studies are warranted to understand the function of these extracellular circulating miRNAs during HCV infection.

Figure 4  Schematic representation of HCV infection associated miRNAs in liver disease progression. Modulated expression of miRNAs regulates the expression of genes involved in several signaling pathways such as, IFN signaling, hepatocyte growth, lipid metabolism, inflammation and fibrosis linked with HCV induced liver disease.
Cross-talk between miRNA and HCV is an emerging area of research. Understanding the potential of manipulating miRNAs as a therapeutic option either alone or in combination with currently available drugs to treat HCV infected patients is still in preliminary stage. Direct involvement of miR-122 in regulating viral replication and pathogenesis has led to the development of the very first miRNA based antiviral therapy. Therapeutic silencing of miR-122 showed long lasting antiviral activity in treatment of naïve HCV patients and no off-target effects in clinical trials. HCV infection modulates several miRNAs that regulate host immune response and cell growth interconnected with multiple signaling pathways (Fig. 4). miRNA mediated regulation of gene expression will help in identifying important signaling networks required towards HCV associated liver disease progression. Indeed, further in-depth studies are needed to identify the mechanistic insights behind modulated miRNAs by HCV infection. Therefore, the identification of miRNAs with a prominent role in HCV viral life cycle and its implication in liver disease progression is exploring a new frontier in the discovery of novel drugs against chronic HCV infections. MicroRNA in circulation is a growing area of research and there are challenges ahead in understanding the cellular origin and functional role of circulatory miRNAs in liver disease progression. Recent studies on circulating miRNAs generate a potential for development of predictive or diagnostic biomarkers to categorize patients with high risk groups for developing end stage liver disease during HCV infection. In addition, circulatory miRNAs is emerging as a tool to assess therapeutic outcome in response to therapy in HCV infected patients.

Conflicts of interest
The authors declare no conflict of interest.

Acknowledgments
This work was supported by research grant DK081817 (RBR) and DK080812 (RR) from the National Institutes of Health and SLU Liver Center Seed Grant (RBR).

References
1. Moradpour D, Penin F. Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol. 2013;369: 113–142.
2. Shulla A, Randall G. Hepatitis C virus-host interactions, replication, and viral assembly. Curr Opin Virol. 2012;2: 725–732.
3. Gravitz L. Introduction: a smouldering public-health crisis. Nature. 2011;474:52–54.
4. Smith BD, Morgan RL, Beckett GA, et al. Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61(RR-4): 1–32.
5. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011;140:1182 e1–1188 e1.
6. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013;19:850–858.
7. Pavlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146:1176–1192.
8. deLemos AS, Chung RT. Hepatitis C treatment: an incipient therapeutic revolution. Trends Mol Med. 2014;20:315–321.
9. Schinazi R, Haltin P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014;34(suppl 1):69–78.
10. Rupp D, Bartenschlager R. Targets for antiviral therapy of hepatitis C. Semin Liver Dis. 2014;34:9–21.
11. Zeisel MB, Luppberger J, Fofana I, Baumert TF. Host-targeting agents for prevention and treatment of chronic hepatitis C – perspectives and challenges. J Hepatol. 2013;58: 375–384.
12. Jolpling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science. 2005;309:1577–1581.
13. Henke JI, Goergen D, Zheng J, et al. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J. 2008;27: 3300–3310.
14. Roberts AP, Lewis AP, Jolpling CL. miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components. Nucleic Acids Res. 2011;39: 7716–7729.
15. Jangra RK, Yi M, Lemon SM. Regulation of hepatitis C virus translation and infectious virus production by the microRNA mir-122. J Virol. 2010;84:6615–6625.
16. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010;327:196–201.
17. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368: 1685–1694.
18. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105.
19. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–233.
20. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11:597–610.
21. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509–524.
22. Haussjer J, Zavolan M. Identification and consequences of miRNA-target interactions—beyond repression of gene expression. Nat Rev Genet. 2014;15:599–612.
23. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009;11:228–234.
24. Ørom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5′UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 2008;30:460–471.
25. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci U S A. 2008;105:1608–1613.
26. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science. 2007;318:1931–1934.
27. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10:704–714.
28. Swaminathan G, Martin-Garcia J, Navas-Martín S. RNA viruses and microRNAs: challenging discoveries for the 21st century. Physiol Genomics. 2013;45:1035–1048.
29. Roberts AP, Lewis AP, Jolpling CL. The role of microRNAs in viral infection. Prog Mol Biol Transl Sci. 2011;102:101–139.
30. Shrivastava S, Mukherjee A, Ray RB. Hepatitis C virus infection, microRNA and liver disease progression. World J Hepatol. 2013;5:479–486.
31. Machlin ES, Sarnow P, Sagan SM. Masking the 5’ terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc Natl Acad Sci U S A. 2011;108:3193–3198.
32. Li Y, Masaki T, Yamane D, McGivern DR, Lemon SM. Competing and noncompeting activities of miR-122 and the 5’ exonuclease Xrn1 in regulation of hepatitis C virus replication. Proc Natl Acad Sci U S A. 2013;110:1881–1886.
33. Nasheri N, Singaravelu R, Goodmurphy M, Lyn RK, Pezacki JP. Hepatitis C virus infection, autophagy and innate immune response. In: Hayat MA, ed. Cancer, Other Pathologies, Inflammation, Immunity, Infection. 2012:486.
34. Shrivastava S, Ray RB. Hepatitis C virus infection modulates expression of cellular microRNAs as an antiviral mechanism. Nature. 2007;449:919–922.
35. Kambara H, Fukuhara T, Shiotaka M, et al. Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122. J Virol. 2012;86:1382–1393.
36. Fukuhara T, Kambara H, Shiotaka M, et al. Expression of microRNA miR-122 facilitates an efficient replication in non-hematopoietic cells upon infection with hepatitis C virus. J Virol. 2012;86:7918–7933.
37. Pedersen IM, Cheng G, Wieland S, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature. 2007;449:919–922.
38. Murakami Y, Tanaka M, Toyoda H, et al. Hepatic microRNA miR-27a regulates homeobox A1 expression. J Virol. 2009;50:453–460.
39. Cheng JC, Yeh YJ, Tseng CP, et al. Let-7b is a novel regulator of hepatitis C virus replication. Cell Mol Life Sci. 2012;69:2621–2633.
40. Mukherjee A, Shrivastava S, Bhanja Chowdhury J, Ray R, Ray RB. Transcriptional suppression of mir-181c by hepatitis C virus enhances homeobox A1 expression. J Virol. 2014;88:7929–7940.
41. Shrivastava S, Ray RB. Hepatitis C virus infection, autophagy and innate immune response. In: Hayat MA, ed. Autophagy. Cancer, Other Pathologies, Inflammation, Immunity, Infection and Aging. vol. 3. Academic Press, Elsevier; 2014:164–190.
42. Bhanja Chowdhury J, Shrivastava S, Steele R, Di Bisceglie AM, Ray R, Ray RB. Hepatitis C virus infection regulates expression of interferon-stimulatory gene IFITM1 by upregulating miR-130A. J Virol. 2012;86:10221–10225.
43. Raychoudhuri A, Shrivastava S, Steele R, Kim H, Ray R, Ray RB. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J Virol. 2011;85:12881–12899.
44. Wilkins C, Woodward J, Lau DT, et al. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology. 2013;57:461–469.
45. Zhang X, Daucher M, Armistead D, Russell R, Kottlit S. MicroRNA expression profiling in HCV-infected human hepatoma cells identifies potential anti-viral targets induced by interferon-α. PLoS ONE. 2013;8:e55733.
46. Li S, Duan X, Li Y, Liu B, McGivray I, Chen L. MicroRNA-130a inhibits HCV replication by restoring the innate immune response. J Virol Hepatol. 2014;21:121–128.
47. Chen Y, Chen J, Wang H, et al. HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. PLoS Pathog. 2013;9:e1003248.
48. Yang Q, Fu S, Wang J. Hepatitis C virus infection decreases the expression of Toll-like receptors 3 and 7 via upregulation of miR-758. Arch Virol. 2014;159:2997–3003.
49. Yoshikawa T, Takata A, Otsuka M, et al. Silencing of microRNA-122 enhances interferon-α signaling in the liver through regulating SOCS3 promoter methylation. Sci Rep. 2012;2:637.
50. Xu G, Yang F, Ding CL, et al. miR-221 accentuates IFN's anti-HCV effect by downregulating SOCS1 and SOCS3. Virology. 2014;462–463:343–350.
51. Bruni R, Marcantoni C, Trittarelli E, et al. An integrated approach identifies IFN-regulated microRNAs and targeted mRNAs modulated by different HCV replicon clones. BMC Genomics. 2011;12:485.
52. Cheng M, Si Y, Niu Y, et al. High-throughput profiling of alpha interferon- and interleukin-28B-regulated microRNAs and identification of let-7s with anti-hepatitis C virus activity by targeting IGF2BP1. J Virol. 2013;87:9707–9718.
53. Murakami Y, Tanaka M, Toyoda H, et al. Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. BMC Med Genomics. 2010;3:48.
54. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med. 2009;15:31–33.
55. Estrabaud E, Lapalus M, Broet P, et al. Reduction of microRNA 122 expression in IFNLR1 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C. J Virol. 2014;88:6394–6402.
56. Köberle V, Waidmann O, Kronenberger B, et al. Serum microRNA-122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy. J Virol Hepat. 2013;20:530–535.
57. Shirasaki T, Honda M, Shimakami T, et al. MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. J Virol. 2013;87:5270–5286.
58. Elhexel DS, Mekky RY, El-Ekiaby N, et al. Predictive prognostic role of miR-181a with discrepancy in the liver and serum of genotype 4 hepatitis C virus patients. Biomed Rep. 2014;2:843–848.
59. McFarland AP, Horner SM, Jarrett A, et al. The favorable IFNLR3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol. 2014;15:72–79.
60. Jiang M, Broering R, Trippler M, et al. MicroRNA-155 controls Toll-like receptor 3- and hepatitis C virus-induced immune responses in the liver. J Virol Hepat. 2014;21:99–110.
61. Bala S, Tilahun Y, Taha O, et al. Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. J Transl Med. 2012;10:151.
62. Hsi E, Huang CF, Dai CY, et al. Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection. Antiviral Res. 2014;105:135–142.
63. Choi Y, Dienes HP, Kravczenko K. Kinetics of miR-122 expression in the liver during acute HCV infection. PLoS ONE. 2013;8:e76501.
64. Fehr C, Conrad KD, Niepmann M. Differential stimulation of hepatitis C virus RNA translation by microRNA-122 in different cell cycle phases. Cell Cycle. 2012;11:277–285.
65. Hou W, Bukong TN, Kodys K, Szabo G. Alcohol facilitates HCV RNA replication via up-regulation of miR-122 expression and inhibition of cyclin G1 in human hepatoma cells. Alcohol Clin Exp Res. 2013;37:599–608.
66. Bukong TN, Hou W, Kodys K, Szabo G. Ethanol facilitates hepatitis C virus replication via up-regulation of GW182 and heat shock protein 90 in human hepatoma cells. Hepatology. 2013;57:70–80.
67. Sgadri H, Mehrab-Mohseni M, Foureau DM, et al. miR-122 decreases HCV entry into hepatocytes through binding to the 3’ UTR of OCLN mRNA. Liver Int. 2014. http://dx.doi.org/10.1111/liv.12698 [Epub ahead of print].
miRNA in HCV infection

68. Hou W, Tian Q, Zheng J, Bonkovsky HL. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. *Hepatology*. 2010;51:1494–1504.

69. Jablonskowsa E, Wójcik K, Szymańska B, Omulecka A, Ciwiklińska H, Piekarska A. Hepatic HMOX1 expression positively correlates with Bach-1 and miR-122 in patients with HCV mono and HIV/HCV coinfection. *PLoS One*. 2014;9:e9564.

70. Peng K, Li Y, Walters KA, et al. Computational identification of hepatitis C virus associated microRNA-mRNA regulatory modules in human livers. *BMc Genomics*. 2009;10:373.

71. Steuerwald NM, Parsons JC, Bennett K, Bates TC, Bonkovsky HL. Parallel microRNA and mRNA expression profiling of (genotype 1b) human hepatoma cells expressing hepatitis C virus. *Liver Int*. 2010;30:1490–1504.

72. Liu X, Wang T, Wakita T, Yang W. Systematic identification of microRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells. *Virology*. 2010;398:57–67.

73. Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis C and liver fibrosis. *Cell Death Differ*. 2003;10(suppl 1):559–567.

74. Marquez RT, Bandyopadhyay S, Wendlant EB, et al. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. *Lab Invest*. 2010;90:1727–1736.

75. Bandyopadhyay S, Friedman RC, Marquez RT, et al. Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture. *J Infect Dis*. 2011;203:1753–1762.

76. Ramachandran S, Ilia Sasha H, Sarma NJ, et al. Hepatitis C virus induced miR200c down modulates FAP-1, a negative regulator of Src signaling and promotes hepatic fibrosis. *PLoS One*. 2013;8:e70744.

77. Sarma NJ, Tiriveedhi V, Subramanian V, et al. Hepatitis C virus mediated changes in miRNA-449a modulates inflammatory biomarker YKL40 through components of the NOTCH signaling pathway. *PLoS One*. 2012;7:e50826.

78. Sarma NJ, Tiriveedhi V, Crippin JS, Chapman WC, Mohanakumar T. Hepatitis C virus-induced changes in microRNA 107 (miRNA-107) and miRNA-449a modulate CCL2 by targeting the interleukin-6 receptor complex in hepatocytes. *J Virol*. 2014;88:3733–3743.

79. Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? *Hepatology*. 2014;59:2403–2412.

80. Singharelu R, Chen R, Lyn RK, et al. Hepatitis C virus induced up-regulation of microRNA-27: a novel mechanism for hepatic steatosis. *Hepatology*. 2014;59:98–108.

81. Boštjanic E, Bandelj E, Luzar B, Poljak M, Glavač D. Hepatic expression of miR-122, miR-126, miR-136 and miR-181a and their correlation to histopathological and clinical characteristics of patients with hepatitis C. *J Viral Hepat*. 2014. http://dx.doi.org/10.1111/jvhe.12265 [Epub ahead of print].

82. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. *J Hepatol*. 2009;50:1142–1154.

83. Law PT, Wong N. Emerging roles of microRNA in the intra-cellular signaling networks of hepatocellular carcinoma. *J Gastroenterol Hepatol*. 2011;26:437–449.

84. Huang S, He X. The role of microRNAs in liver cancer progression. *Br J Cancer*. 2011;104:235–240.

85. Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? *Hepatology*. 2013;57:840–847.

86. Zhang Y, Wei W, Cheng N, et al. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. *Hepatology*. 2012;56:1631–1640.

87. Banauda K, Kaliszewski M, Korolnek T, et al. MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes. *Hepatology*. 2011;53:53–61.

88. Huang S, Xie Y, Yang P, Chen P, Zhang L. HCV core protein-induced down-regulation of microRNA-152 promoted aberrant proliferation by regulating Wnt1 in HepG2 cells. *PLoS One*. 2014;9:e81730.

89. Ishida H, Tatsami T, Hosui A, et al. Alterations in microRNA expression profile in HCV-infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. *Biochem Biophys Res Commun*. 2011;412:92–97.

90. Varnhol H, Drebber U, Schulze F, et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. *Hepatology*. 2008;47:1223–1232.

91. Ura S, Honda M, Yamashita T, et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. *Hepatology*. 2009;49:1098–1112.

92. Lemoine N, Thabut D, Housse C, et al. The emerging roles of microvesicles in liver diseases. *Nat Rev Gastroenterol Hepatol*. 2014;11:350–361.

93. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. *Nat Rev Clin Oncol*. 2014;11:145–156.

94. Shrivastava S, Petronie J, Steele R, Lauer GM, Bisceglie AM, Ray RB. Upregulation of circulating miR-20a is correlated with hepatitis C virus mediated liver disease progression. *Hepatology*. 2013;58:863–871.

95. Shwetha S, Gouthamchandra K, Chandra M, Ravishankar B, Khaja MN, Das S. Circulating microRNA profile in HCV infected serum: novel insight into pathogenesis. *Sci Rep*. 2013;3:1555.

96. Bihrer V, Friedrich-Rust M, Kronenberger B, et al. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. *Am J Gastroenterol*. 2011;106:1663–1669.

97. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. *PLoS One*. 2011;6:e23937.

98. Starkey Lewis PJ, Dear J, Platt V, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. *Hepatology*. 2011;54:1767–1776.

99. Bala S, Petrasek J, Mundkur S, et al. Circulating microRNAs in exosomes indicate hepatitis and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. *Hepatology*. 2012;56:1946–1957.

100. van der Meer AJ, Farid WR, Sonneveld MJ, et al. Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122. *J Viral Hepat*. 2013;20:158–166.

101. Bihrer V, Waidmann O, Friedrich-Rust M, et al. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. *PLoS One*. 2011;6:e26971.

102. Trebicka J, Anadol E, Elfimova N, et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. *J Hepatol*. 2013;58:234–239.

103. Abdalla MA, Haj-Ahmad Y. Promising candidate urinary microRNA biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus Egyptian patients. *J Cancer*. 2012;3:19–31.